Discovery, Structure, and Anticancer Activity of an Iridium Complex of Diselenobenzoquinone

Authors

  • Dr. Hani Amouri,

    1. Institut Parisien de Chimie Moléculaires, IPCM, UMR CNRS 7201; Université Pierre et Marie Curie, Paris 6, 4 place Jussieu, case 42, 75252 Paris Cedex 05 (France), Fax: (33) 1-4427-3841
    Search for more papers by this author
  • Dr. Jamal Moussa,

    1. Institut Parisien de Chimie Moléculaires, IPCM, UMR CNRS 7201; Université Pierre et Marie Curie, Paris 6, 4 place Jussieu, case 42, 75252 Paris Cedex 05 (France), Fax: (33) 1-4427-3841
    Search for more papers by this author
  • Dr. Anna K. Renfrew,

    1. Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Féderale de Lausanne (EPFL), 1015 Lausanne (Switzerland)
    Search for more papers by this author
  • Prof. Paul J. Dyson,

    1. Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Féderale de Lausanne (EPFL), 1015 Lausanne (Switzerland)
    Search for more papers by this author
  • Dr. Marie Noelle Rager,

    1. NMR Facitilties of Ecole Nationale Supérieure de Chimie de Paris, 11 rue Pierre et Marie Curie, 75231 Paris Cedex 05 (France)
    Search for more papers by this author
  • Lise-Marie Chamoreau

    1. Institut Parisien de Chimie Moléculaires, IPCM, UMR CNRS 7201; Université Pierre et Marie Curie, Paris 6, 4 place Jussieu, case 42, 75252 Paris Cedex 05 (France), Fax: (33) 1-4427-3841
    Search for more papers by this author

  • This work was supported by the CNRS, by the Université Pierre et Marie Curie-Paris 6, and by the Swiss National Science Foundation, which we gratefully acknowledge.

Abstract

original image

Caught in the act: The first stable η4-diseleno-p-benzoquinone complex, [Cp*Ir(η4-C6H4Se2)], has been isolated. The X-ray structure (see picture; Ir magenta, Se yellow) confirms the coordination of the elusive diselenobenzoquinone intermediate. The anticancer activity of this complex was compared to related oxygen and sulfur analogues; only the diseleno complex was cytotoxic, having a comparable activity to cisplatin.

Ancillary